EP1007723A4 - Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis - Google Patents

Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis

Info

Publication number
EP1007723A4
EP1007723A4 EP98942081A EP98942081A EP1007723A4 EP 1007723 A4 EP1007723 A4 EP 1007723A4 EP 98942081 A EP98942081 A EP 98942081A EP 98942081 A EP98942081 A EP 98942081A EP 1007723 A4 EP1007723 A4 EP 1007723A4
Authority
EP
European Patent Office
Prior art keywords
granzymes
methods
binding molecules
treating diseases
diseases characterized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98942081A
Other languages
German (de)
French (fr)
Other versions
EP1007723A1 (en
Inventor
Judy Lieberman
Paul J Beresford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Disease Institute Inc
Original Assignee
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Institute Inc filed Critical Immune Disease Institute Inc
Publication of EP1007723A1 publication Critical patent/EP1007723A1/en
Publication of EP1007723A4 publication Critical patent/EP1007723A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
EP98942081A 1997-08-18 1998-08-17 Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis Withdrawn EP1007723A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5633397P 1997-08-18 1997-08-18
US56333 1997-08-18
PCT/US1998/017022 WO1999009206A1 (en) 1997-08-18 1998-08-17 Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis

Publications (2)

Publication Number Publication Date
EP1007723A1 EP1007723A1 (en) 2000-06-14
EP1007723A4 true EP1007723A4 (en) 2001-11-28

Family

ID=22003721

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98942081A Withdrawn EP1007723A4 (en) 1997-08-18 1998-08-17 Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis

Country Status (3)

Country Link
EP (1) EP1007723A4 (en)
CA (1) CA2298867A1 (en)
WO (1) WO1999009206A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034910A2 (en) * 2000-10-25 2002-05-02 University Of Alberta Method for modulating granzyme b uptake and for identifying modulators thereof
DE60331228D1 (en) * 2002-08-23 2010-03-25 Multhoff Gabriele GRANZYME B AS A HSP70 / HSP70 PEPTIDE-DEPENDANT APOPTOSAUSES IN TUMOR CELLS
US20040248158A1 (en) 2003-01-28 2004-12-09 Loughran Thomas P Differentially expressed genes in large granular lymphocyte leukemia
WO2005110453A2 (en) 2004-04-12 2005-11-24 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017489A (en) * 1985-06-28 1991-05-21 Massachusetts Institute Of Technology Cytotoxic T lymphocte serine esterase and method for stimulation and inhibition
US5712117A (en) * 1995-02-08 1998-01-27 Zymogenetics, Inc. Cytoplasmic antiproteinase-2 and coding sequences

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 133, no. 22, 27 November 2000, Columbus, Ohio, US; abstract no. 307966, XP002177247 *
M. COUNIS ET AL.: "DNases and apoptosis", BIOCHEMISTRY AND CELL BIOLOGY, vol. 78, no. 4, 1 April 2000 (2000-04-01), Montreal Canada, pages 405 - 414 *
See also references of WO9909206A1 *

Also Published As

Publication number Publication date
EP1007723A1 (en) 2000-06-14
CA2298867A1 (en) 1999-02-25
WO1999009206A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
EP1015578A4 (en) Therapeutic molecules
HUP0001237A3 (en) Methods for treating vascular disorders
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
DE69713295D1 (en) AZABICYCLISHE CARBANIUMSAUREESTER FOR THERAPEUTIC USE
HUP0003964A2 (en) Methods for treating thrombotic disorders
PL346271A1 (en) Therapies for treating pulmonary diseases
AU3673499A (en) Hydrogel for the therapeutic treatment of aneurysms
AU9403798A (en) Human regulatory molecules
AU8769098A (en) System for treating patients with anxiety disorders
DE69736862D1 (en) GENETIC TREATMENT SYSTEM FOR HEARING DISORDERS
NO20004688D0 (en) Therapy for estrogen-associated disorders
AU8800598A (en) B7-binding molecules for treating immune diseases
HK1031174A1 (en) Compositions and methods for treating diabetes
IL132758A0 (en) Methods for treating inflammation and inflammatory diseases using padprt
IL134718A0 (en) Treatment of conduct disorder
AU1184399A (en) Therapeutic molecules
EP1039883A4 (en) Methods for the treatment of apolipoprotein e related diseases
EP1007723A4 (en) Methods for using granzymes and binding molecules thereof for treating diseases characterized by abnormal apoptosis
AU6242498A (en) Methods for treating central and peripheral nerve pain
AU5855899A (en) Method for identifying substances for the treatment of c-jun-mediated disorders
DE69806062D1 (en) COMBINATION THERAPY FOR TREATING AIDS
AU1282099A (en) Method for treatment of disorders of attention
EP1124555A4 (en) Method of treating neurodegenerative diseases
DE19639312B4 (en) Compress for heat therapy
AUPM885894A0 (en) Therapeutic molecules

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/02 A, 7C 12N 1/38 B, 7A 61K 38/10 B, 7C 12Q 1/37 B, 7C 12Q 1/25 B, 7G 01N 33/50 B, 7A 61K 38/48 B, 7C 12N 9/64 B, 7A 61K 38/17 B

A4 Supplementary search report drawn up and despatched

Effective date: 20011017

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BERESFORD, PAUL, J.

Inventor name: LIEBERMAN, JUDY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030228